Resensitization of methicillin-resistant Staphylococcus aureus by amoxapine, an FDA-approved antidepressant
- PMID: 29349359
- PMCID: PMC5767979
- DOI: 10.1016/j.heliyon.2017.e00501
Resensitization of methicillin-resistant Staphylococcus aureus by amoxapine, an FDA-approved antidepressant
Abstract
The rapid increase in bacterial resistance to antibiotics is a global healthcare crisis. Non-antibiotic pharmaceuticals that have attained approval by the United States Food and Drug Administration have the potential to be repurposed as bacterial resistance-modifying agents and therefore could become valuable resources in our battle against antibiotic-resistant microbes. Amoxapine is a tetracyclic antidepressant used in the treatment of major depressive disorder. Here we demonstrate the ability of amoxapine to resensitize methicillin-resistant Staphylococcus aureus strain ATCC 43300 to oxacillin in both agar diffusion and broth microdilution assays. Amoxapine also reduced the bacterial cleavage of nitrocefin in a dose-dependent manner, suggesting that it may exert its adjuvant effects through reduction of beta-lactamase activity.
Keywords: Microbiology.
Figures


References
-
- Gross M. Antibiotics in crisis. Curr. Biol. 2013;23:R1063–R1065. - PubMed
-
- Costelloe C., Metcalfe C., Lovering A., Mant D., Hay A.D. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. Br. Med. J. 2010;340:c2096. - PubMed
-
- Clatworthy A.E., Pierson E., Hung D.T. Targeting virulence: a new paradigm for antimicrobial therapy. Nat. Chem. Biol. 2007;3:541–548. - PubMed
-
- Quadri F., Mazer-amirshahi M., Fox E.R., Hawley K.L., Pines J.M., Zocchi M.S., May L. Antibacterial drug shortages from 2001 to 2013: implications for clinical practice. Clin. Infect. Dis. 2015;60:1737–1742. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases